Pre‐therapy inflammation and coagulation activation and long‐term CD4 count responses to the initiation of antiretroviral therapy
Achhra A, Phillips A, Emery S, MacArthur R, Furrer H, De Wit S, Losso M, Law, groups I. Pre‐therapy inflammation and coagulation activation and long‐term CD4 count responses to the initiation of antiretroviral therapy. HIV Medicine 2015, 16: 449-454. PMID: 25959989, PMCID: PMC5676307, DOI: 10.1111/hiv.12258.Peer-Reviewed Original ResearchConceptsCD4 count responseBaseline CD4 countC-reactive proteinCD4 countART initiationClinical outcomesCoagulation activationBiomarker levelsInterleukin-6Therapy trialsMedian baseline CD4 countAntiretroviral Therapy (SMART) trialFirst-line ARTInflammatory marker levelsHIV-positive individualsLong-term CD4CD4 count measurementCD4 responseART-naïveCent of individualsStudy armsD-dimerCount responseMean ageMarker levelsKidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
Achhra A, Mocroft A, Ross M, Ryom L, Lucas G, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell J, Wyatt C, Group I. Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine 2015, 16: 55-63. PMID: 25711324, PMCID: PMC4341947, DOI: 10.1111/hiv.12234.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseCD4 cell countPrevalence of CKDART-naïve adultsGlomerular filtration rateUrine proteinCell countAntiretroviral therapyBaseline characteristicsKidney diseaseFiltration rateHigher CD4 cell countsTraditional CKD risk factorsCKD risk factorsHigher CD4 countsCells/μLCells/μL.AntiRetroviral Treatment (START) studyClinical trial participantsRace/ethnicityCD4 countHIV infectionRisk factorsLow prevalenceTrial participants